Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.74 USD | +0.64% | +13.40% | +90.62% |
05-09 | Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating | MT |
05-08 | Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+90.62% | 1.45B | |
+32.85% | 709B | |
+30.77% | 595B | |
-1.75% | 367B | |
+20.17% | 334B | |
+5.99% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.41% | 171B |
- Stock Market
- Equities
- TARS Stock
- News Tarsus Pharmaceuticals, Inc.
- Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target